keyword
MENU ▼
Read by QxMD icon Read
search

Strattera

keyword
https://www.readbyqxmd.com/read/27663942/atomoxetine-and-parent-training-for-children-with-autism-and-attention-deficit-hyperactivity-disorder-a-24-week-extension-study
#1
Tristram Smith, Michael G Aman, L Eugene Arnold, Laura B Silverman, Luc Lecavalier, Jill Hollway, Rameshwari Tumuluru, Susan L Hyman, Kristin A Buchan-Page, Jessica Hellings, Robert R Rice, Nicole V Brown, Xueliang Pan, Benjamin L Handen
OBJECTIVE: The authors previously reported on a 2-by-2 randomized clinical trial of individual and combined treatment with atomoxetine (ATX) and parent training (PT) for attention-deficit/hyperactivity disorder (ADHD) symptoms and behavioral noncompliance in 128 5- to 14-year-old children with autism spectrum disorder. In the present report, they describe a 24-week extension of treatment responders and nonresponders. METHOD: One-hundred seventeen participants from the acute trial (91%) entered the extension; 84 of these were in 2 subgroups: "treatment responders" (n = 43) from all 4 groups in the acute trial, seen monthly for 24 weeks, and "placebo nonresponders" (n = 41), treated with open-label ATX for 10 weeks...
October 2016: Journal of the American Academy of Child and Adolescent Psychiatry
https://www.readbyqxmd.com/read/26730199/a-critical-appraisal-of-atomoxetine-in-the-management-of-adhd
#2
REVIEW
Ann C Childress
Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder beginning in childhood and often continuing into adulthood. A wealth of data shows that ADHD symptoms respond well to pharmacological treatment. Stimulant medications, including amphetamine and methylphenidate, are most commonly used to treat ADHD. However, with the approval of atomoxetine (Strattera(®), [ATX]) by the US Food and Drug Administration in late 2002, an effective non-stimulant option became available. The US Food and Drug Administration approved ATX for the treatment of ADHD in children, adolescents, and adults...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/25772636/suboptimal-dosing-of-strattera-atomoxetine-for-adhd-patients
#3
David B Clemow
To raise awareness, this article provides a commentary on the frequent underdosing of atomoxetine for the treatment of adult attention-deficit/hyperactivity disorder (ADHD) that may be associated with poor patient outcomes. Data suggest an adequate atomoxetine dose for sufficient duration is important for ADHD symptom improvement. Despite the recommended 80 mg/day target dose, real-world data show that an approximately 60 mg/day average adult atomoxetine dose is utilized. This article discusses the factors that may contribute to this suboptimal dosing...
September 2014: Postgraduate Medicine
https://www.readbyqxmd.com/read/25507271/suboptimal-dosing-of-strattera-atomoxetine-for-adhd-patients
#4
David B Clemow
To raise awareness, this article provides a commentary on the frequent underdosing of atomoxetine for the treatment of adult attention-deficit/hyperactivity disorder (ADHD) that may be associated with poor patient outcomes. Data suggest an adequate atomoxetine dose for sufficient duration is important for ADHD symptom improvement. Despite the recommended 80 mg/day target dose, real-world data show that an approximately 60 mg/day average adult atomoxetine dose is utilized. This article discusses the factors that may contribute to this suboptimal dosing...
September 2014: Postgraduate Medicine
https://www.readbyqxmd.com/read/25420287/suboptimal-dosing-of-strattera-atomoxetine-for-adhd-patients
#5
David B Clemow
To raise awareness, this article provides a commentary on the frequent underdosing of atomoxetine for the treatment of adult attention-deficit/hyperactivity disorder (ADHD) that may be associated with poor patient outcomes. Data suggest an adequate atomoxetine dose for sufficient duration is important for ADHD symptom improvement. Despite the recommended 80 mg/day target dose, real-world data show that an approximately 60 mg/day average adult atomoxetine dose is utilized. This article discusses the factors that may contribute to this suboptimal dosing...
September 2014: Postgraduate Medicine
https://www.readbyqxmd.com/read/24554298/adhd-medication-trends-in-turkey-2009-2013
#6
Ozgür Oner, Esra Safak Yilmaz, Hasan Karada X011f, Mert Vural, Elif Hilal Vural, Akif Akbulat, Hakk X0131 Gürsöz, Hakan Türkçapar, Saim Kerman
Objective: To investigate the change of ADHD medication prescriptions in Turkey between 2009 and 2013. Method: Consumption data of ADHD medications, immediate release (IR) methylphenidate (MPH; Ritalin), OROS MPH (Concerta), and atomoxetine (Strattera) were obtained from IMS Health database for the November 2008 to October 2013 period. Defined daily dose (DDD) of each drug was calculated according to WHO definitions and time-series analysis was conducted. Results: There was a significant seasonal effect for prescription of all drugs...
February 19, 2014: Journal of Attention Disorders
https://www.readbyqxmd.com/read/24167677/a-12-week-nursing-support-programme-for-carers-of-children-and-adolescents-in-the-uk-with-attention-deficit-hyperactivity-disorder-prescribed-atomoxetine
#7
Nicola Savill, Jeremy Pelton, Alan Lenox-Smith, Chris J Bushe
INTRODUCTION: Patient support programmes are assuming greater importance in the UK in many therapeutic areas, mostly with the aim of improving adherence to medication and many being provided by the pharmaceutical industry. Atomoxetine is a noradrenaline reuptake inhibitor for the treatment of attention deficit hyperactivity disorder that has recently demonstrated incremental efficacy for at least 12 weeks. Issues of adherence may be predicted over this initial period particularly if adverse events are reported...
April 2013: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/23397050/a-review-of-the-abuse-potential-assessment-of-atomoxetine-a-nonstimulant-medication-for-attention-deficit-hyperactivity-disorder
#8
REVIEW
Himanshu P Upadhyaya, Durisala Desaiah, Kory J Schuh, Frank P Bymaster, Mary J Kallman, David O Clarke, Todd M Durell, Paula T Trzepacz, David O Calligaro, Eric S Nisenbaum, Paul J Emmerson, Leslie M Schuh, Warren K Bickel, Albert J Allen
RATIONALE: Treatment of attention-deficit/hyperactivity disorder (ADHD) has for many years relied on psychostimulants, particularly various formulations of amphetamines and methylphenidate. These are central nervous system stimulants and are scheduled because of their abuse potential. Atomoxetine (atomoxetine hydrochloride; Strattera®) was approved in 2002 for treatment of ADHD, and was the first nonstimulant medication approved for this disorder. It was classified as an unscheduled medication indicating a low potential for abuse...
March 2013: Psychopharmacology
https://www.readbyqxmd.com/read/23285704/examination-of-antimicrobial-activity-of-selected-non-antibiotic-medicinal-preparations
#9
Hanna Kruszewska, Tomasz Zareba, Stefan Tyski
The aim of this study was to detect and characterize the antimicrobial activity of non-antibiotic drugs, selected from the pharmaceutical products analyzed during the state control performed in National Medicines Institute, Warszawa, Poland. In 2010, over 90 pharmaceutical preparations have been randomly chosen from different groups of drugs. The surveillance study was performed on standard ATCC microbial strains used for drug control: S. aureus, E. coli, P. aeruginosa and C. albicans. It was shown that the drugs listed below inhibited growth of at least one of the examined strains: Arketis 20 mg tab...
November 2012: Acta Poloniae Pharmaceutica
https://www.readbyqxmd.com/read/23047788/atomoxetine-use-during-a-period-of-fda-actions
#10
Dongyi Tony Du, Esther H Zhou, John Goldsmith, Clark Nardinelli, Tarek A Hammad
CONTEXT: The Food and Drug Administration (FDA) issued a Public Health Advisory entitled "Suicidal Thinking in Children and Adolescents Being Treated with Strattera (Atomoxetine)" on September 29, 2005. At FDA's request, the manufacturer subsequently added a boxed warning to the drug's labeling on November 8, 2005. OBJECTIVE: To evaluate whether the boxed warning for suicidal thinking in atomoxetine's labeling was associated with a change in the pattern of attention-deficit/hyperactivity disorder (ADHD) medication use...
November 2012: Medical Care
https://www.readbyqxmd.com/read/21765848/cardiovascular-side-effects-of-atomoxetine-and-its-interactions-with-inhibitors-of-the-cytochrome-p450-system
#11
Pashtoon Murtaza Kasi, Rawad Mounzer, George H Gleeson
Attention deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders of childhood and adolescence. Classically, stimulants have been used in the treatment of this condition. Atomoxetine (Strattera; Eli Lilly and Company) is a selective norepinephrine reuptake inhibitor (SNRI), one of the first medications in the nonstimulant class of medications that has been approved by the FDA for the treatment of ADHD. Atomoxetine is a phenoxypropylamine derivative and is structurally related to the antidepressant fluoxetine...
2011: Case Reports in Medicine
https://www.readbyqxmd.com/read/21611939/-stimulant-and-non-stimulant-medication-in-current-and-future-therapy-for-adhd
#12
REVIEW
A G Franke, A Konrad, K Lieb, M Huss
The current pharmacotherapy for attention-deficit hyperactivity disorder (ADHD) is mainly based on the stimulant methylphenidate and to a small extent on amphetamines which are not approved in Germany. The only approved non-stimulant so far is atomoxetin (Strattera®), a norepinephrine reuptake inhibitor. There is no approved pharmacotherapy for adults. The aim of the available medication is a reduction of impulsivity, hyperactivity, and attention deficits. Neurobiological correlates of these effects are still not fully understood, however, a functional implication of dopaminergic and noradrenergic systems is known...
March 2012: Fortschritte der Neurologie-Psychiatrie
https://www.readbyqxmd.com/read/21258431/less-discontinuation-of-adhd-drug-use-since-the-availability-of-long-acting-adhd-medication-in-children-adolescents-and-adults-under-the-age-of-45-years-in-the-netherlands
#13
Els van den Ban, Patrick C Souverein, Hanna Swaab, Herman van Engeland, Toine C G Egberts, Eibert R Heerdink
Treatment options for ADHD in the Netherlands have increased with the introduction of the extended-release formulations of methylphenidate (MPH ER, Concerta(®)) in 2003 and atomoxetine (ATX, Strattera(®)) in 2005, but data on the effect on drug usage patterns are scarce. The objective of the present study was to describe changes in the patterns of ADHD medication use and determinants thereof among children, adolescents and adults (<45 years) starting ADHD medication since the introduction of MPH ER and ATX...
December 2010: Attention Deficit and Hyperactivity Disorders
https://www.readbyqxmd.com/read/21206410/atomoxetine-induced-myocardial-infarction
#14
Ali Seifi, Heidi Griffith, Sahar Avestimehr, Haitham Dib
Atomoxetine (Strattera®, Eli Lilly and Co.) is the first non-stimulant drug in the United States (US) to be approved for the treatment of attention deficit hyperactivity disorder (ADHD). In the past, physicians have been concerned about the safety of a variety of ADHD medications. As a result, non-stimulant drugs were developed with claims of fewer side effects and limited abuse potential. The data regarding this new group of drugs and its effect on the cardiovascular system is limited. We report a case of atomoxetine induced myocardial infarction (MI) in a young woman...
February 2011: Southern Medical Journal
https://www.readbyqxmd.com/read/21183129/advances-in-the-treatment-of-attention-deficit-hyperactivity-disorder-a-guide-for-pediatric-neurologists
#15
REVIEW
Sharon B Wigal, Stephanie Chae, Avni Patel, Robin Steinberg-Epstein
The purpose of this article is to assist pediatric neurologists in practice and in training to better understand and distinguish between several of the most commonly prescribed treatments for attention-deficit/hyperactivity disorder (ADHD) in school-aged children. Among the various pharmacotherapies available for ADHD, 4 specific medications will be reviewed: oral release osmotic system methylphenidate hydrochloride (CON; Concerta, McNeil Pharmaceuticals), lisdexamfetamine dimesylate (LDX; Vyvanse, Shire Pharmaceuticals), atomoxetine (ATX; Strattera, Eli Lilly), and guanfacine extended-release (GXR; Intuniv, Shire Pharmaceuticals)...
December 2010: Seminars in Pediatric Neurology
https://www.readbyqxmd.com/read/21179640/attention-deficit-hyperactivity-disorder-pharmacotherapy
#16
Josephine Elia
Pharmacotherapy, one of the effective modalities of treatment for attention deficit/hyperactivity disorder (ADHD), was discovered serendipitously and, until recently, consisted primarily of short-acting methylphenidate and dextroamphetamine compounds. The US Food and Drug Administration's (FDA) approval of Concerta in 2000 followed by approval of additional long-acting methylphenidate (Ritalin LA; Metadate CD) and amphetamine formulations (Adderall XR) expanded the repertoire. By providing sustained efficacy for most of the school day, mid-day administration is avoided, privacy is preserved, and adherence to treatment improves...
January 2005: Psychiatry
https://www.readbyqxmd.com/read/20711324/strattera-ups-downs-and-emerging-uses
#17
Elisa F Cascade, Amir H Kalali, David Feifel
Although overall prescribing of atomoxetine hydrochloride (HCI) (Strattera) continues to decline, recent anecdotal reports suggest emerging uses of the product in combination therapy. In this article we examine trends in atomoxetine (HCI) prescribing as well as use in combination with other psychotropic classes. An expert commentary is provided on the data.
April 2007: Psychiatry
https://www.readbyqxmd.com/read/20030421/spotlight-on-atomoxetine-in-attention-deficit-hyperactivity-disorder-in-children-and-adolescents
#18
REVIEW
Karly P Garnock-Jones, Gillian M Keating
Atomoxetine (Strattera) is a selective noradrenaline (norepinephrine) reuptake inhibitor that is not classified as a stimulant, and is indicated for use in patients with attention-deficit hyperactivity disorder (ADHD). Atomoxetine is effective and generally well tolerated. It is significantly more effective than placebo and standard current therapy and does not differ significantly from, or is noninferior to, immediate-release methylphenidate; however, it is significantly less effective than the extended-release methylphenidate formulation OROS methylphenidate (hereafter referred to as osmotically released methylphenidate) and extended-release mixed amfetamine salts...
January 2010: CNS Drugs
https://www.readbyqxmd.com/read/19738568/-effectiveness-of-strattera-in-children-and-adolescents-with-attention-deficit-hyperactivity-disorder
#19
COMPARATIVE STUDY
I N Vakula, Iu Sh Vasianina, Z Kh Gorbunova, E Iu Nikiforova, E I Ponomarenko
A group of children and adolescents with ADHD (25 boys and 9 girls), aged 6-17 years, were treated with strattera in the optimum dose (1,2 mg/day) on an outpatient basis. The assessment of treatment effectiveness showed the marked and moderately pronounced clinical effect in 78,1% patients after 3 months. The psychological study revealed a positive trend in the volume and speed of switching attention in 80% of children and the improvement of sustainability of attention - in 69%. Control EEG revealed the decrease in the <index of deceleration> in 70,2% of patients...
2009: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/19445548/atomoxetine-a-review-of-its-use-in-attention-deficit-hyperactivity-disorder-in-children-and-adolescents
#20
REVIEW
Karly P Garnock-Jones, Gillian M Keating
Atomoxetine (Strattera(R)) is a selective norepinephrine (noradrenaline) reuptake inhibitor that is not classified as a stimulant, and is indicated for use in patients with attention-deficit hyperactivity disorder (ADHD). Atomoxetine is effective and generally well tolerated. It is significantly more effective than placebo and standard current therapy and does not differ significantly from or is noninferior to immediate-release methylphenidate; however, it is significantly less effective than the extended-release methylphenidate formulation OROS(R) methylphenidate (hereafter referred to as osmotically released methylphenidate) and extended-release mixed amfetamine salts...
2009: Paediatric Drugs
keyword
keyword
98649
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"